• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·605266.SS
Share

Jianzhijia Pharmaceutical Chain Group Co., Ltd. Stocks

CN¥ 16.01Last Updated 30.09.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

CN¥ 369.75M

CN¥ 16.01
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Yunnan Jianzhijia Health-Chain Co., Ltd. operates a significant pharmaceutical retail enterprise throughout China. This company oversees an extensive chain of roughly 1,200 proprietary stores, complemented by its digital pharmacy platform. Shoppers can find a broad spectrum of items, encompassing household medications, vision care products like contact lenses and their solutions, various medical devices, sexual wellness goods, nutritional supplements, traditional Chinese herbal medicines, personal hygiene articles, infant products, and even ready-to-eat convenience foods. Established in Kunming, China, in 2004, the company maintains its headquarters there.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 15:36

Morning in New York: Oil Caught Between De-escalation and the Risk of New Attacks

12.10.2026 15:03

The Nobel Prize in Economics was awarded to the authors of new approaches to crisis management

12.10.2026 14:48

Slow but sure—a tsunami: IMF chief warns that AI is hitting the labor market and government budgets

12.10.2026 14:28

The CEOs of Broadcom and Intel have identified the main challenge facing AI development. It is not a chip shortage.

12.10.2026 13:09

The Saudis announced that they had intercepted new missiles. Riyadh promises stable oil supplies

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026